Zhitong Finance App News, Baiyunshan (00874) announced that recently, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. (hereinafter referred to as “Mingxing Pharmaceutical”), a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration. The dopamine hydrochloride injection has made a supplementary application according to the quality and efficacy consistency evaluation reporting channel, thus obtaining approval from the State Drug Administration to change the relevant content.

According to the announcement, Mingxing Pharmaceutical's dopamine hydrochloride injection has obtained additional drug application approval, which is conducive to enhancing the market competitiveness of the drug.